Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
10.1172/jci88877 J
FDA approves Lilly's Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials While not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators in a key secondary endpoint Mounjaro represents the first new class of diabetes medicines introduced in nearly a decade and is expected to be available in the As the first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones
The staff was professional, the clinic is beautiful, and I felt refreshed almost immediately after the treatment
If you have concerns about elevated cortisol or symptoms suggestive of Cushing's syndrome (such as unexplained weight gain, purple striae, or muscle weakness), it is essential to consult your GP for appropriate investigation, which may include cortisol testing and referral to an endocrinologist
Tirzepatide helps with liver fat, but the glucagon-mediated effect in retatrutide is in a different category entirely
